Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 19, Number 11—November 2013

Severe Plasmodium vivax Malaria in Pakistan

Ali Bin Sarwar Zubairi, Sobia Nizami, Afsheen Raza, Vikram Mehraj, Anita Fazal Rasheed, Najia Karim Ghanchi, Zahra Nur Khaled, and M. Asim BegComments to Author 
Author affiliations: Aga Khan University, Karachi, Pakistan (A.B.S. Zubairi, S. Nizami, A. Raza, A.F. Rasheed, N.K. Ghanchi, Z.N. Khaled, M.A. Beg); Aix Marseille Université, Marseille, France (V. Mehraj)

Main Article

Table 1

Demographic profile of study participants with Plasmodium vivax and P. falciparum malaria, Karachi, Pakistan, 2009–2011*

Frequency (%)
P. vivax
P. falciparum
F       98 (33) 12 (25)       6 (46)
M       198 (67) 35 (75)       7 (54)
Previously healthy adults       189 (64) 30 (64) 10 (77)
Concurrent illness
Diabetes       49 (17)       4 (9)       0
Ischemic heart disease       37 (12)       2 (4)       3 (23)
Chronic kidney disease       10 (3)       3 (6)       0
Co-existing infection†       34 (12)       5 (11)       0
Others‡       10 (3)       5 (11)       0
Total§ 107 (36) 17 (36) 3 (23)

*n = 356.
†Co-existing infections included dengue fever, urinary tract infection, enteric fever, and hepatitis C, diagnosed by appropriate serologic testing/culture.
‡Other conditions included chronic obstructive pulmonary disease, chronic liver disease, malignancy, and other conditions from the Charlson Comorbidity Index (5).
§Many patients had multiple comorbidities; therefore, the total does not sum the above.

Main Article

  1. World Health Organization. World malaria report: 2011. Geneva: The Organization; 2011.
  2. Imwong  M, Pukrittayakamee  S, Grüner  AC, Rénia  L, Letourneur  F, Looareesuwan  S, Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1. Malar J. 2005;4:20 . DOIPubMedGoogle Scholar
  3. Zakeri  S, Bereczky  S, Naimi  P, Pedro Gil  J, Djadid  ND, Färnert  A, Multiple genotypes of the merozoite surface proteins 1 and 2 in Plasmodium falciparum infections in a hypoendemic area in Iran. Trop Med Int Health. 2005;10:10604. DOIPubMedGoogle Scholar
  4. World Health Organization. Guidelines for the treatment of malaria, 2nd ed. Geneva: The Organization; 2010.
  5. Sundararajan  V, Henderson  T, Perry  C, Muggivan  A, Quan  H, Ghali  WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57:128894. DOIPubMedGoogle Scholar
  6. Beg  MA, Sani  N, Mehraj  V, Jafri  W, Khan  MA, Malik  A, Comparative features and outcomes of malaria at a tertiary care hospital in Karachi, Pakistan. Int J Infect Dis. 2008;12:3742. DOIPubMedGoogle Scholar
  7. Price  RN, Douglas  NM, Anstey  NM. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis. 2009;22:4305. DOIPubMedGoogle Scholar
  8. Douglas  NM, Anstey  NM, Buffet  PA, Poespoprodjo  JR, Yeo  TW, White  NJ, The anaemia of Plasmodium vivax malaria. Malar J. 2012;11:135. DOIPubMedGoogle Scholar
  9. Sharma  A, Khanduri  U. How benign is benign tertian malaria? J Vector Borne Dis. 2009;46:1414 .PubMedGoogle Scholar
  10. Kochar  DK, Das  A, Kochar  SK, Saxena  V, Sirohi  P, Garg  S, Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in northwestern India. Am J Trop Med Hyg. 2009;80:1948 .PubMedGoogle Scholar
  11. Mueller  I, Galinski  MR, Baird  JK, Carlton  JM, Kochar  DK, Alonso  PL, Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis. 2009;9:55566 . DOIPubMedGoogle Scholar

Main Article

Page created: October 31, 2013
Page updated: October 31, 2013
Page reviewed: October 31, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.